Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Apr 15;120(15):2325–2333. doi: 10.1002/cncr.28669

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

PMC Copyright notice

A 2-factor score for estimating the risk of gastrointestinal stromal tumor (GIST) recurrence during and after adjuvant imatinib based on tumor mitotic count and site. (A) Kaplan-Meier plots show the influence of the score on recurrence-free survival (lowest risk, gastric GIST with ≤ 10 mitoses per 50 high-power fields of the microscope or nongastric GIST with ≤ 5 mitoses; intermediate high risk, gastric GIST with 11 to 50 mitoses or nongastric GIST with 6 to 20 mitoses; highest risk, gastric GIST with > 50 mitoses or nongastric GIST with > 20 mitoses per 50 high-power fields). (B) Influence of the predictive groups on recurrence-free survival stratified by the duration of adjuvant imatinib administered. (C) Kaplan-Meier plots show the influence of the score on recurrence-free survival in the ACOSOG Z9001 cohort.